Literature DB >> 24732593

Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment.

R Fu1, M Xuan1, Y Zhou1, T Sun1, J Bai1, Z Cao1, L Zhang1, H Li1, D Zhang1, X Zhang1, C Lv1, F Xue1, X Liu1, R Yang1, L Zhang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24732593     DOI： 10.1038/leu.2014.138

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

2.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Authors:  Tiziano Barbui; Guido Finazzi; Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Heinz Gisslinger; Veronika Buxhofer-Ausch; Valerio De Stefano; Silvia Betti; Alessandro Rambaldi; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

3.  Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

Authors:  A Tefferi; T L Lasho; C Finke; A A Belachew; E A Wassie; R P Ketterling; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

4.  CALR mutation studies in chronic neutrophilic leukemia.

Authors:  Terra L Lasho; Michelle A Elliott; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2014-03-07       Impact factor: 10.047

5.  CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.

Authors:  Paola Guglielmelli; Jyoti Nangalia; Anthony R Green; Alessandro M Vannucchi
Journal:  Am J Hematol       Date:  2014-03-11       Impact factor: 10.047

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  16 in total

Review 1.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

2.  JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Hiraku Takei; Yongjin Yoo; Murim Choi; Yoshitaka Sunami; Yumi Hironaka; Masaaki Noguchi; Michiaki Koike; Naohiro Noda; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

3.  Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Authors:  Luca Malcovati; Elisa Rumi; Mario Cazzola
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

4.  Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.

Authors:  Munazza Rashid; Rifat Zubair Ahmed; Shariq Ahmed; Muhammad Nadeem; Nuzhat Ahmed; Tahir Sultan Shamsi
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-09       Impact factor: 0.900

Review 5.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

6.  A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.

Authors:  Yining Yang; Xiaorui Wang; Chun Wang; Youwen Qin
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

Review 7.  Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.

Authors:  N Saki; R Shirzad; F Rahim; A Saki Malehi
Journal:  Clin Transl Oncol       Date:  2017-02-15       Impact factor: 3.405

8.  Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.

Authors:  Eun-Hyung Yoo; Kyung-Jin Park; Hong-Hee Won; Jun-Hee Park; Jong-Ho Park; Seung-Tae Lee; Hee-Jin Kim; Soo-Mee Bang; Hyun-Sook Chi; Chul Won Jung; Sun-Hee Kim; Hongseok Yun; Choong-Hyun Sun; Inho Park; Seungmook Lee; Clarence Lee; Barry Merriman; Raymond Luo; Eileen Hwee Hong Tan; Keun-Joon Park; Na-Kyung Yoo; Jason J Kang; Jong-Won Kim
Journal:  J Clin Lab Anal       Date:  2016-05-02       Impact factor: 2.352

9.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

10.  Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis.

Authors:  K-H Lim; Y-C Chang; C Gon-Shen Chen; H-C Lin; W-T Wang; Y-H Chiang; H-I Cheng; N-W Su; J Lin; Y-F Chang; M-C Chang; R-K Hsieh; Y-Y Kuo; W-C Chou
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.